Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
A PHASE 3, RANDOMIZED, DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162b2 IN ADULTS 65 YEARS OF AGE AND OLDER
Sponsor: Pfizer
This PHASE3 trial investigates COVID-19 and Pneumococcal Disease and is currently completed. Pfizer leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Feb 2022 — Apr 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
Status: Not Yet Recruiting → Active Not Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
May 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .